Abstract: An aqueous pharmaceutical composition adapted for parenteral administration of tapentadol or a physiologically acceptable salt thereof having a pH value of at least 5.4.

Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.

Abstract: Aspects of the present disclosure relate to providing secure access to resources of a private network. For example, a client device may transmit a request identifying the protected resource to an authentication server. The authentication server queries a network address lookup table to identify a network address of the protected resource based on the identifying information of the request. If the network address denotes a network location that is not generally accessible, the authentication server generates a resource record that identifies a bastion host, a port, and a connection method for accessing the protected resource. The resource record and the network address may then be transmitted to the client device. In response, the client device may use the information in the resource record to establish a tunnel connection with the bastion host, and the client device uses the tunnel connection to access the protected resource via the bastion host.

Abstract: The invention relates to the use of compounds which exhibit an affinity for the ?-opioid receptor of at least 100 nM (Ki value, human) and an affinity for the ORL-1 receptor, wherein the ratio between the affinities ORL1/? defined as 1/[Ki(ORL1)/Ki(?)] is from 0.1 to 30, for the treatment of pain.

Abstract: The invention relates to substituted phenylureas and phenylamides, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.

Abstract: Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds, and a method of using these compounds in the treatment and/or inhibition of pain and further diseases and/or disorders mediated at least in part via the vanilloid receptor 1 (VR1/TRPV1).

Abstract: Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions.

Abstract: Active compound combinations of compounds of group A, particularly opioids such as (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or a salt thereof with a physiologically tolerated acid, and compounds of group B, particularly anti-muscarine agents such as oxybutynin or a salt thereof with a physiologically tolerated acid suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.

Abstract: Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions.

Abstract: The invention relates to aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Abstract: The invention relates to substituted phenylureas and phenylamides, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.

Abstract: Aspects of the present disclosure relate to providing secure access to resources of a private network. For example, a client device may transmit a request identifying the protected resource to an authentication server. The authentication server queries a network address lookup table to identify a network address of the protected resource based on the identifying information of the request. If the network address denotes a network location that is not generally accessible, the authentication server generates a resource record that identifies a bastion host, a port, and a connection method for accessing the protected resource. The resource record and the network address may then be transmitted to the client device. In response, the client device may use the information in the resource record to establish a tunnel connection with the bastion host, and the client device uses the tunnel connection to access the protected resource via the bastion host.

Abstract: Vanilloid receptor ligand compounds corresponding to formula I: a process for producing such compounds, pharmaceutical compositions containing them, and the use of such compounds to treat pain and various other vanilloid receptor mediated conditions.

Abstract: Vanilloid receptor ligand compounds corresponding to formula I: pharmaceutical compositions containing such compounds, a process for producing such compounds, and methods of using such compounds for treating or inhibiting pain and various other disorders or conditions.

Abstract: The invention relates to amine substituted methanesulfonamide derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Abstract: The present invention relates to novel vanilloid receptor ligands, to a process for the production thereof, to pharmaceutical preparations containing these compounds and to the use of these compounds for the production of pharmaceutical preparations.

Abstract: Compounds corresponding to formula I: which act as vanilloid receptor ligands, pharmaceutical compositions containing such compounds, a process for the producing such compounds, and the use thereof to treat or inhibit pain and/or various other disorders or conditions.

Abstract: The invention relates to substituted phenylureas and phenylamides, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.

Abstract: Aspects of the present disclosure relate to providing secure access to resources of a private network. For example, a client device may transmit a request identifying the protected resource to an authentication server. The authentication server queries a network address lookup table to identify a network address of the protected resource based on the identifying information of the request. If the network address denotes a network location that is not generally accessible, the authentication server generates a resource record that identifies a bastion host, a port, and a connection method for accessing the protected resource. The resource record and the network address may then be transmitted to the client device. In response, the client device may use the information in the resource record to establish a tunnel connection with the bastion host, and the client device uses the tunnel connection to access the protected resource via the bastion host.

Abstract: The present invention relates to novel vanilloid receptor ligands, to a process for the production thereof, to pharmaceutical preparations containing these compounds and to the use of these compounds for the production of pharmaceutical preparations.